FDA Inspection 1222097 — Taisho Pharmaceutical (M) SDN BHD
The FDA completed an inspection of Taisho Pharmaceutical (M) SDN BHD on Nov 2, 2023 in Bandar Baru Bangi. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 5 citations were issued during this inspection. Product area: Food/Cosmetics.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Nov 2, 2023
- Fiscal Year
- 2024
- Product Type
- Food/Cosmetics
- Project Area
- Food Composition, Standards, Labeling and Econ
- Location
- Bandar Baru Bangi (Malaysia)
Citations
| ID | CFR | Description |
|---|---|---|
| 15579 | 21 CFR 111.155(c)(1) | Components - representative samples |
| 15829 | 21 CFR 111.70(b)(1) | Specifications - component identity |
| 15858 | 21 CFR 111.75(a)(1)(i) | Component - verify identity, dietary ingredient |
| 15861 | 21 CFR 111.75(a)(2)(ii)(A) | Component - qualify supplier |
| 4464 | 21 CFR 108.25(c)(1) | Registration |